Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Phase 2 Terminated 10 enrolled Anne Chang Novartis Pharmaceuticals · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2015-02
Primary completion: 2017-04
Completion: 2017-06

Publications

Results Tran DC, Moffat A, Brotherton R, Pague A, Zhu GA, Chang ALS. An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas. J Am Acad Dermatol. 2018 May;78(5):1011-1013.e3. doi: 10.1016/j.jaad.2017.11.031. Epub 2017 Nov 23. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buparlisib	Small molecule	80 mg	Oral
Subject	Sonidegib	Small molecule	200 mg	Oral

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications